Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following statements about biotransformation is NOT true?

Conversion of polar to less polar compounds. **Explanation:** The primary goal of **biotransformation (metabolism)** is to facilitate the excretion of drugs from the body. To achieve this, the body converts **lipid-soluble (non-polar)** compounds into **water-soluble (polar)** compounds. Polar compounds are less likely to be reabsorbed in the renal tubules and are easily excreted in urine. Therefore, the statement that biotransformation converts polar to less polar compounds is **incorrect**. **Analysis of Options:** * **Option B (Correct Answer):** As stated, metabolism aims to increase polarity. Converting a polar drug into a less polar (lipid-soluble) one would lead to its reabsorption into the systemic circulation, defeating the purpose of excretion. * **Option A & D:** While metabolism often inactivates drugs, it can also generate **active metabolites** from active drugs (e.g., Diazepam to Oxazepam) or activate an inactive **prodrug** (e.g., Enalapril to Enalaprilat). * **Option C:** This is the fundamental principle of Phase I and Phase II reactions—increasing hydrophilicity to ensure the drug is "trapped" in the urine. **NEET-PG High-Yield Pearls:** * **Phase I Reactions:** Include Oxidation (most common), Reduction, and Hydrolysis. They introduce/unmask a functional group. * **Phase II Reactions:** Include Glucuronidation (most common), Acetylation, and Methylation. These are **true detoxification** steps that significantly increase polarity. * **Exception to Polarity:** In rare cases, metabolism can make a drug less soluble, such as the **acetylation of sulfonamides**, which can lead to crystalluria. * **Prodrug Example:** Levopa is converted to Dopamine; Prednisone is converted to Prednisolone.

Q: A 75 kg person is administered a drug with a half-life of 3 hours. What is the approximate clearance of the drug?

23 mL/min. ⚠️ **Note:** This question cannot be solved using standard pharmacokinetic formulas without the volume of distribution (Vd). The answer relies on estimation principles rather than exact calculation. ***23 mL/min*** - This represents a **low to moderate clearance** value, typical for drugs that undergo hepatic metabolism with low-to-intermediate extraction ratios - For context: Normal **creatinine clearance** (marker of GFR) is approximately 90-120 mL/min in adults [1], so 23 mL/min represents roughly 20-25% of renal clearance capacity - This is a plausible value for drugs with **predominantly hepatic metabolism** with low hepatic extraction ratio - Using the relationship $Cl = \frac{0.693 \times Vd}{t_{1/2}}$, this would correspond to a Vd of approximately 6 liters (if t½ = 3 hours) [2] *210 mL/min* - This represents **moderate to high clearance**, suggesting efficient elimination - Comparable to **renal plasma flow** (approximately 600-700 mL/min × filtration fraction) - Would require a Vd of approximately 54 liters with the given half-life - Typical for drugs with good renal excretion or intermediate hepatic extraction *1670 mL/min* - This is extremely high clearance, approaching **total hepatic blood flow** (1500 mL/min) - Would require Vd of approximately 433 liters, which exceeds total body water (42L in a 70kg person) - Only seen with high extraction ratio drugs (>0.7) with extensive first-pass metabolism - Physiologically implausible for most drugs *6770 mL/min* - This clearance is **physiologically impossible** as it exceeds cardiac output (5-6 L/min = 5000-6000 mL/min) [3] - Clearance cannot exceed the blood flow to the eliminating organ [3] - Clearly a distracter option with no pharmacokinetic validity

Q: Which statement best describes the relationship between drug potency and efficacy in dose-response curves?

Drug B is the most efficacious. ***Drug B is the most efficacious*** - **Efficacy** refers to the **maximum effect (Emax)** a drug can produce, represented by the plateau height of the dose-response curve on the y-axis - **Drug B's curve reaches the highest point**, indicating it produces the greatest maximal blocking effect (~100 units) - **This makes Drug B the most efficacious drug** among the three, as it can produce the largest therapeutic response regardless of how much drug is given - Efficacy order: Drug B > Drug C > Drug D *Drug C is the most potent* - **Potency** refers to the amount of drug needed to produce a given effect, measured by **EC50** (the concentration producing 50% of maximal effect) - **The lower the EC50, the more potent the drug** (curve shifted to the left) - **Drug B has the lowest EC50** (its curve is furthest to the left), making it the most potent drug, not Drug C - Drug C requires a higher concentration than Drug B to achieve 50% effect, so it is less potent - Potency order: Drug B > Drug C > Drug D *Drug C is as efficacious as drug D* - **Drug C has higher efficacy than Drug D** because its curve reaches a higher plateau on the y-axis - Drug C achieves a maximal blocking effect of approximately 100 units, while Drug D reaches only approximately 75 units - **Different efficacy values** mean they are not equally efficacious - A drug's efficacy is independent of the dose required and depends only on the maximum achievable effect *Drug D is more potent than drug C* - **Drug C is actually more potent than Drug D**, not the reverse - Drug C's dose-response curve is **shifted to the left** of Drug D's curve, indicating a lower EC50 - This means **Drug C requires a lower concentration** to achieve 50% of its maximal effect compared to Drug D - The leftward shift indicates greater potency for Drug C

Q: Loading dose of an oral drug depends on all of the following except?

Half-life. ***Correct Answer: Half-life*** - **Half-life** primarily determines the **maintenance dose** and **dosing interval**, not the loading dose - The **loading dose (LD)** is calculated to rapidly achieve the desired therapeutic **plasma concentration** using the formula: **LD = (Cp × Vd) / F** - Half-life determines how long it takes to reach steady state (4-5 half-lives) and how frequently maintenance doses should be given - The loading dose bypasses the waiting time by immediately achieving therapeutic levels *Incorrect: Volume of distribution* - **Vd** is a mandatory parameter in the calculation of the loading dose formula - It determines how widely the drug distributes in the body relative to the target plasma concentration - A higher **Vd** necessitates a higher loading dose to saturate tissue binding sites and achieve therapeutic plasma levels quickly *Incorrect: Plasma concentration* - The loading dose is specifically calculated to quickly achieve the desired therapeutic **steady-state plasma concentration (Cp)** - The target concentration (Cp) is central to the loading dose calculation and appears in the numerator of the formula - The goal of the loading dose is to bypass the time required to reach this concentration with maintenance doses alone *Incorrect: Bioavailability* - **Bioavailability (F)** represents the fraction of the administered drug that reaches systemic circulation - It is crucial for oral drugs where absorption may be incomplete due to first-pass metabolism or incomplete absorption - The loading dose formula includes **F** in the denominator (LD = (Cp × Vd) / F) to adjust for incomplete absorption

Q: The effect of both drugs given together on the blood pressure of a patient was evaluated in comparison with the effect of individual drugs on BP. The following curve represents: (Recent NEET Pattern 2016-17)

Synergism. ***Synergism*** - The graph shows that the effect of drugs A and B when given together (A+B) is significantly **greater than the sum of their individual effects**. - This amplified effect, where the combined response is more than the simple addition of individual responses, is the definition of **synergism** (also called potentiation or supra-additive effect). *Summation* - Summation occurs when the **combined effect** of two drugs is **equal to the arithmetic sum** of their individual effects. - In the depicted graph, the peak effect of A+B is clearly much higher than the sum of the peaks of A and B individually, ruling out simple summation. *Additive effects* - Additive effects are synonymous with summation, meaning the combined effect is precisely the sum of individual effects. - The graph demonstrates a response that **exceeds a simple additive effect**, indicating a synergistic interaction rather than mere additive action. *Antagonism* - **Antagonism** occurs when one drug reduces or blocks the effect of another drug, resulting in a combined effect that is **less than the sum** of individual effects. - In the depicted graph, the combined effect (A+B) clearly shows enhancement rather than reduction, ruling out antagonism.

Q: A new sedative-hypnotic drug is being evaluated in preclinical toxicity studies. The following quantal dose-response curve is obtained showing the hypnotic effect and lethal effect. Calculate the therapeutic index of the drug being tested.

1.8. The image shows a **quantal dose-response curve** depicting the percentage of subjects responding to increasing doses for two effects: **hypnosis** (therapeutic effect) and **death** (toxic effect). The **Therapeutic Index (TI)** is calculated as **TI = LD50/ED50**. **Steps to calculate:** 1. **Determine ED50 for Hypnosis** (therapeutic effect): - Locate 50% response on the Y-axis - Trace horizontally to intersect the "Hypnosis" curve - Trace vertically down to the X-axis (log dose) - ED50 ≈ **2.5** on the log dose scale 2. **Determine LD50 for Death** (toxic effect): - Locate 50% response on the Y-axis - Trace horizontally to intersect the "Death" curve - Trace vertically down to the X-axis (log dose) - LD50 ≈ **4.5** on the log dose scale 3. **Calculate Therapeutic Index:** - **TI = LD50 / ED50 = 4.5 / 2.5 = 1.8** ***Correct Option: 1.8*** - This is the correct therapeutic index calculated from the ratio of LD50 to ED50 - A TI of 1.8 indicates a relatively narrow margin of safety between therapeutic and lethal doses - Higher TI values indicate safer drugs *Incorrect Option: 0.56* - This would be the reciprocal calculation (ED50/LD50), which is not how TI is defined - TI is always LD50/ED50, not the reverse *Incorrect Option: 2.5* - This is the ED50 value (effective dose for hypnosis), not the therapeutic index - This represents only one component of the TI calculation *Incorrect Option: 4.5* - This is the LD50 value (lethal dose), not the therapeutic index - This represents only the numerator in the TI calculation

Q: The following curve shows a graded dose-response curve. Drug A and drug B are bronchodilators. What do drug C and D represent?

C = Competitive antagonist, D = Noncompetitive antagonist. ***C = Competitive antagonist, D = Noncompetitive antagonist*** - Curve C, representing a **competitive antagonist**, shifts the dose-response curve of the agonist to the **right** without reducing the maximal effect. This indicates that a higher concentration of the agonist is needed to overcome the antagonist and achieve the same maximal response. - Curve D, representing a **noncompetitive antagonist**, reduces the **maximal effect** of the agonist and does not significantly shift the curve to the right in the same manner as a competitive antagonist would for the full maximal effect of the agonist. The maximal effect is *permanently* reduced even with increasing agonist concentration. *Noncompetitive antagonist, D = Competitive antagonist* - This is incorrect because a **noncompetitive antagonist** reduces the maximal effect, which is depicted by curve D, while a **competitive antagonist** shifts the curve to the right without reducing maximal effect, as seen in curve C. - The roles of C and D are reversed in this option. *C = Agonist, D = Partial agonist* - This is incorrect as C and D are clearly shown to be modulating the effect of "bronchodilators" (A and B), indicating they are likely antagonists affecting the primary drugs, not agonists themselves. - A **partial agonist** would produce a lower maximal effect than a full agonist, but would still show a dose-response curve with an increasing effect, not a flat line limiting the maximal effect like D. *C = Agonist, D = Competitive antagonist* - This is incorrect as C represents a shift in the agonist's curve, typical of a **competitive antagonist**, not an agonist itself. - If C were an agonist, it would have its own dose-response curve showing increasing effect, similar to A and B.

Q: What do A and B represent in the curve shown below?

A= Median effective dose, B= Median lethal dose. ***A= Median effective dose, B= Median lethal dose*** - **A** corresponds to the **median effective dose (ED50)**, which is the dose that produces a therapeutic effect in 50% of the population - The purple curve represents the dose-response for efficacy; at A, 50% of individuals are responding effectively - **B** corresponds to the **median lethal dose (LD50)**, which is the dose that is lethal to 50% of the population - The red curve represents the dose-response for toxicity/lethality; at B, 50% of individuals are experiencing a lethal outcome *A= Therapeutic index, B= Median efficacy* - The **therapeutic index** is a ratio (LD50/ED50), not a specific dose represented on the x-axis - **Median efficacy** is not a standard pharmacological term to represent a point on a dose-response curve; rather, efficacy refers to the maximal effect a drug can produce *A= Median lethal dose, B= Median effective dose* - This option reverses the correct identification of A and B - **Median effective dose (ED50)** is typically expected at lower doses, while **median lethal dose (LD50)** is at higher doses, indicating toxicity - In the provided graph, the curve for A occurs at a much lower dose range than the curve for B, making it the effective dose, not the lethal dose *A= Median efficacy, B= Therapeutic index* - **Median efficacy** is not a specific dose value represented this way on a dose-response curve - The **therapeutic index** is a ratio, not a dose point on the graph

Q: Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?

Brand A is bioequivalent to brand B. ***Brand A is bioequivalent to brand B*** - **Bioequivalence** is generally established if the **90% confidence interval** for the ratio of the **AUC** (and Cmax) of the test product (Brand B) to the reference product (Brand A) falls within **80-125%**. - Here, the ratio of AUC (Brand B / Brand A) is 115/124 ≈ 0.927 or 92.7%. This value falls well within the accepted range of 80-125%, indicating bioequivalence. *Brand A is not bioequivalent to brand B* - This statement is incorrect because the AUC ratio (115/124 ≈ 0.927) is within the **standard bioequivalence range of 80-125%**, indicating that the two brands are indeed bioequivalent. - While there are differences in Cmax and Tmax for the two brands as shown in the graph, the provided AUC values suggest bioequivalence for the overall drug exposure. *Brand A has higher volume of distribution than brand B* - The provided **AUC values** (Area Under the Curve) primarily reflect the **extent of drug exposure** and are not directly indicative of the **volume of distribution (Vd)**. - Vd is a pharmacokinetic parameter that relates the total amount of drug in the body to the concentration of the drug in plasma, and it cannot be directly inferred from AUC values alone without additional information like dose and clearance. *Brand B has higher volume of distribution than brand A* - Similar to the previous option, AUC values alone are insufficient to determine the relative **volume of distribution** between the two brands. - Changes in Vd would affect the peak concentration (Cmax) and the elimination half-life, but a definitive conclusion requires more comprehensive pharmacokinetic analysis.

Question 1

Which of the following statements about biotransformation is NOT true?

Accepted Answer

Conversion of polar to less polar compounds

Answer

Active metabolite generation

Answer

Conversion of less polar to more polar compounds

Answer

Generation of active drug from a prodrug

Question 2

A 75 kg person is administered a drug with a half-life of 3 hours. What is the approximate clearance of the drug?

Accepted Answer

23 mL/min

Answer

6770 mL/min

Answer

1670 mL/min

Answer

210 mL/min

Question 3

Which statement best describes the relationship between drug potency and efficacy in dose-response curves?

Accepted Answer

Drug B is the most efficacious

Answer

Drug C is as efficacious as drug D

Answer

Drug D is more potent than drug C

Answer

Drug C is the most potent

Question 4

Loading dose of an oral drug depends on all of the following except?

Accepted Answer

Half-life

Answer

Volume of distribution

Answer

Plasma concentration

Answer

Bioavailability

Question 5

The effect of both drugs given together on the blood pressure of a patient was evaluated in comparison with the effect of individual drugs on BP. The following curve represents: (Recent NEET Pattern 2016-17)

Accepted Answer

Synergism

Answer

Summation

Answer

Additive effects

Answer

Antagonism

Question 6

A new sedative-hypnotic drug is being evaluated in preclinical toxicity studies. The following quantal dose-response curve is obtained showing the hypnotic effect and lethal effect. Calculate the therapeutic index of the drug being tested.

Accepted Answer

1.8

Answer

4.5

Answer

2.5

Answer

0.56

Question 7

Which is correct about the curves shown?

Accepted Answer

A= Graded dose response curve, B= Dose response curve

Answer

A= Dose response curve, B= Graded dose response curve

Answer

A= Quantal dose response curve, B= Dose response curve

Answer

A= Dose response curve, B= Quantal dose response curve

Question 8

The following curve shows a graded dose-response curve. Drug A and drug B are bronchodilators. What do drug C and D represent?

Accepted Answer

C = Competitive antagonist, D = Noncompetitive antagonist

Answer

C = Noncompetitive antagonist, D = Competitive antagonist

Answer

C = Agonist, D = Partial agonist

Answer

C = Agonist, D = Competitive antagonist

Question 9

What do A and B represent in the curve shown below?

Accepted Answer

A= Median effective dose, B= Median lethal dose

Answer

A= Therapeutic index, B= Median efficacy

Answer

A= Median lethal dose, B= Median effective dose

Answer

A= Median efficacy, B= Therapeutic index

Question 10

Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?

Accepted Answer

Brand A is bioequivalent to brand B

Answer

Brand A is not bioequivalent to brand B

Answer

Brand A has higher volume of distribution than brand B

Answer

Brand B has higher volume of distribution than brand A

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?